Severin Schwan - Roche Holding CEO and Director
| RHHVF Stock | USD 241.51 9.28 3.70% |
CEO
Dr. Severin Schwan was Chairman of the Corporationrationrate Executive Committee, Chief Executive Officer and Executive Director of Roche Holding Ltd since 2013. He was Chairman of the Corporationrationrate Executive Committee and Chief Executive Officer of Roche Holding AG from March 4, 2008. He was previously Chief Executive Officer of the Division Roche Diagnostics and Member of the Corporationrationrate Executive Committee at the Company from January 1, 2006. Between 1993 and 1995, he was a Trainee at Corporationrationrate Finance for Roche Basel. From 1995 until 1998, he was Head of Finance Administration at Roche Brussels. From 1998 until 2000, Dr. Schwan was Head Finance Informatics at Roche Grenzach, Germany and Member of the Executive Board of Roche Deutschland Holding GmbH. From 2000 until 2004, he was Head of Global Finance Services at Roche Diagnostics, Basel. Since 2009, Dr. Schwan was Member of the Board of Directors of Chugai Pharmaceuticals, Japan, and Member of the International Business Leaders Advisory Council for the Mayor of Shanghai . Dr. Schwan studied Economics at Universitaet Innsbruck, University of York and University of Oxford. He gained an Economics Degree from Innsbruck. He studied Law at Universitaet Innsbruck and gained a Law degree in 1991 since 2013.
| Age | 56 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | CEO Age | ||
| Deborah Waterhouse | GlaxoSmithKline PLC ADR | N/A | |
| Chris Ilsley | Novartis AG ADR | N/A | |
| Joseph Jimenez | Novartis AG ADR | 58 | |
| Andrew Witty | GlaxoSmithKline PLC ADR | 50 | |
| Javier Ribes | Grifols SA ADR | N/A | |
| Emma Walmsley | GlaxoSmithKline PLC ADR | 55 | |
| Richard Saynor | Novartis AG ADR | 57 | |
| Paul Hudson | Novartis AG ADR | 51 | |
| Nacho Abia | Grifols SA ADR | 56 | |
| Bruno Strigini | Novartis AG ADR | N/A | |
| Akira Kurokawa | Santen Pharmaceutical Co | 65 | |
| Victor Deu | Grifols SA ADR | N/A | |
| Brian McNamara | GlaxoSmithKline PLC ADR | 49 | |
| William Anderson | Roche Holding Ltd | 57 | |
| Michael Heuer | Roche Holding Ltd | 64 | |
| Osamu Nagayama | Roche Holding Ltd | 69 | |
| Francesco Balestrieri | Novartis AG ADR | N/A | |
| Albert Roura | Grifols SA ADR | N/A | |
| Naveed Shams | Santen Pharmaceutical Co | ||
| Michael Ball | Novartis AG ADR | 62 | |
| Elizabeth Barrett | Novartis AG ADR | 56 | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
| Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
| Bruno Eschli, Head Relations | ||
| Silvia Ayyoubi, Head of Group HR | ||
| Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Beatrice Mauro, Non-Executive Director | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
| James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
| Gottlieb Keller, General Counsel and Corporate Secretary | ||
| Urs Jaisli, Chief Compliance Officer | ||
| Daniel ODay, COO of Pharmaceuticals division | ||
| Claudia Bockstiegel, G Counsel | ||
| DeAnne Julius, Non-Executive Director | ||
| Johannes MD, Head Devel | ||
| Karl Mahler, Head of Investor Relations | ||
| Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
| John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
| Claudia Dyckerhoff, Non-Executive Director | ||
| Fritz Gerber, Honorary Chairman of the Board | ||
| Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
| Julie Brown, Non-Executive Director | ||
| Richard Lifton, Non-Executive Director | ||
| Paul Bulcke, Non-Executive Director | ||
| Christoph Franz, Non-Executive Director | ||
| PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
| Pascale Schmidt, Chief Officer | ||
| Pius Baschera, Non-Executive Director | ||
| Peter Voser, Non-Executive Director | ||
| Bernard Poussot, Non-Executive Director | ||
| John Bell, Non-Executive Director | ||
| Andreas Oeri, Non-Executive Director | ||
| Alan Hippe, CFO and IT Officer | ||
| William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
| F Hoffmann, IR Contact Officer | ||
| Severin Schwan, CEO and Director | ||
| Anita Hauser, Non-Executive Director | ||
| Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 287.91 B | |||
| Shares Outstanding | 693.89 M | |||
| Shares Owned By Institutions | 40.30 % | |||
| Price To Earning | 18.04 X | |||
| Price To Book | 9.57 X | |||
| Price To Sales | 3.97 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Roche Holding in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Roche Holding's short interest history, or implied volatility extrapolated from Roche Holding options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding AG. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Roche OTC Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |